CN108273012A - 一种治疗晚期外伤性癫痫的中药丸 - Google Patents
一种治疗晚期外伤性癫痫的中药丸 Download PDFInfo
- Publication number
- CN108273012A CN108273012A CN201810376527.2A CN201810376527A CN108273012A CN 108273012 A CN108273012 A CN 108273012A CN 201810376527 A CN201810376527 A CN 201810376527A CN 108273012 A CN108273012 A CN 108273012A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- leech
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 62
- 230000000472 traumatic effect Effects 0.000 title claims abstract description 42
- 206010027336 Menstruation delayed Diseases 0.000 title claims abstract description 38
- 239000006187 pill Substances 0.000 title claims abstract description 35
- 241000545744 Hirudinea Species 0.000 claims abstract description 36
- 244000197580 Poria cocos Species 0.000 claims abstract description 34
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 34
- 241000255789 Bombyx mori Species 0.000 claims abstract description 27
- 210000000941 bile Anatomy 0.000 claims abstract description 26
- 241000489492 Arisaema Species 0.000 claims abstract description 24
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 24
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 24
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 23
- 241000756943 Codonopsis Species 0.000 claims abstract description 23
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 23
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 23
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 23
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 23
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 241000721047 Danaus plexippus Species 0.000 claims description 5
- 241001251949 Xanthium sibiricum Species 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 23
- 206010010904 Convulsion Diseases 0.000 abstract description 22
- 230000001737 promoting effect Effects 0.000 abstract description 21
- 230000036461 convulsion Effects 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 15
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 13
- 208000026435 phlegm Diseases 0.000 abstract description 13
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000005906 menstruation Effects 0.000 abstract description 5
- 238000004393 prognosis Methods 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 5
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 abstract description 3
- 210000003710 cerebral cortex Anatomy 0.000 abstract description 3
- 230000000803 paradoxical effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000002082 anti-convulsion Effects 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001037 epileptic effect Effects 0.000 description 17
- 206010019196 Head injury Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 206010034759 Petit mal epilepsy Diseases 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 231100000862 numbness Toxicity 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 229960000623 carbamazepine Drugs 0.000 description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000037012 Psychomotor seizures Diseases 0.000 description 4
- 230000003556 anti-epileptic effect Effects 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000002877 Epileptic Syndromes Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010044684 Trismus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000028492 myoclonic seizure Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000332007 Arisaema erubescens Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 208000005053 encephalomalacia Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000028326 generalized seizure Diseases 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- -1 stable Chemical compound 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗晚期外伤性癫痫的中药丸，属中药丸制作技术领域。它由下述重量份的原料组成：水蛭10‑40份,地龙10‑18份,当归10‑18份,桃仁10‑18份,天麻10‑18份,郁金10‑15份,胆南星10‑18份,僵蚕10‑18份,党参10‑15份,甘草20‑50份,代赭石10‑30份,山药10‑18份,泽泻10‑18份,丹参10‑18份,川芎10‑30份,茯苓10‑18份。具有活血散瘀通经，清火化痰，行气活血，明显改善脑血管动力和大脑皮层异常放电，镇惊定痫抗惊厥功效，快速缓解和消除患者即发症状，副作用小，用药时间短，疗效优于纯西药治疗，改善预后及预防难治性癫痫发生，治愈率高，不易复发。
Description
技术领域
本发明涉及一种治疗晚期外伤性癫痫的中药丸，属中药丸制作技术领域。
背景技术
外伤性癫痫（PTE）是指继发于颅脑损伤后的癫痫性发作，可发生在伤后的任何时间，早者于伤后即刻出现，晚者可在颅脑损伤愈后多年发作。外伤性癫痫(PTE)是颅脑损伤后的严重并发症之一，可以导致脑组织的严重缺氧，在原发性颅脑损伤的基础上进一步加重患者脑组织的病理损伤及神经生化改变，并可能引发循环和呼吸功能障碍，增加颅内出血风险，加重脑水肿，以至引起昏迷、颅内压增高甚至形成脑疝，导致病情恶化，增大死亡风险。
晚期外伤性癫痫患者约占57%，其往往会习惯性反复发作，对家庭生活和经济是双重沉重打击，目前单纯采用西药丙戊酸钠、卡马西平、安定、苯巴比妥等进行抗癫痫治疗，疗效差强人意，用药时间偏长，药物副反应多，长期使用会引起白细胞、血小板减少，损伤肝肾功能，刺激消化道等副作用，而一旦停药后又极易复发。因此，探索中西医结合治疗晚期外伤性癫痫新方法，研制一种副作用小，用药时间短，疗效好，不易复发的治疗晚期外伤性癫痫的中药丸是非常具有临床意义的。
发明内容
本发明的目的在于，针对上述现有技术的不足，提供一种可快速缓解和消除患者即发症状，副作用小，用药时间短，疗效好，有助于改善预后及预防难治性癫痫发生，治愈率高，近、远期疗效均优于纯西药治疗，且不易复发的治疗晚期外伤性癫痫的中药丸。
本发明是通过如下的技术方案来实现上述目的的：
一种治疗晚期外伤性癫痫的中药丸，其特征在于：它是通过下述重量份的原料制成：
水蛭10-40份 地龙10-18份 当归10-18份
桃仁10-18份 天麻10-18份 郁金10-15份
胆南星10-18份 僵蚕10-18份 党参10-15份
甘草20-50份 代赭石10-30份
山药10-18份 泽泻10-18份 丹参10-18份
川芎10-30份 茯苓10-18份
该治疗晚期外伤性癫痫的中药丸，根据中医辩证论治和标本兼治原则，及癫痫病的发病病因，通过本发明申请人数年临床实践和探索，采用水蛭、地龙、当归、桃仁、天麻、郁金、胆南星、僵蚕、党参、甘草、代赭石、山药、泽泻、丹参、川芎、茯苓这16味中草药组合配方，其中的君药为：水蛭、代赭石、地龙、僵蚕、胆南星，臣药为：川芎、当归、桃仁、丹参、天麻、郁金,佐药为：党参、茯苓、山药、泽泻，使药为：甘草。并在临床中辅以西药（根据发作类型用药，大发作和局限性发作者,予以丙戊酸钠口服，每次两片，每日三次；小发作者予以丙戊酸钠口服，每次一片，每日三次；精神运动发作者予以卡马西平口服，每次两片，每日三次；肌阵挛发作者予以安定片口服，每次一片，每日三次。）即中西医结合针对治疗晚期外伤性癫痫取得了稳定和不错的疗效，不仅能快速缓解和消除癫痫症状，而且对改善预后、减少发病次数、预防癫痫发作的效果明显优于纯西药治疗，有效提高了治愈率。
优选的，上述中药组合物由以下重量份的组分组成：
水蛭20-40份 地龙15-18份 当归15-18份
桃仁15-18份 天麻15-18份 郁金12-15份
胆南星15-18份 僵蚕15-18份 党参10-15份
甘草40-50份 代赭石20-30份
山药15-18份 泽泻15-18份 丹参15-18份
川芎20-30份 茯苓15-18份
进一步优选的，上述中药组合物由以下重量份的组分组成：
水蛭20份 地龙15份 当归15份
桃仁15份 天麻15份 郁金12份
胆南星15份 僵蚕15份 党参10份
甘草40份 代赭石20份
山药15份 泽泻15份 丹参15份
川芎20份 茯苓15份
所述该治疗晚期外伤性癫痫的中药丸是通过如下方法制作而成的：将水蛭、泽泻、当归、茯苓粉碎成粗粉备用，余药煎煮二次，第一次加水2000ml煮沸3小时，第二次加水1000ml煮沸2小时，滤液合并，静置24小时，取上清液浓缩至稠膏，将稠膏倒入上诉由水蛭、泽泻、当归、茯苓粉碎而成的粗粉中混匀，80℃干燥，粉碎成细粉，过80目筛，用纯净水泛丸，即得成品，0.38g/丸，瓶装密封，60g/瓶。
该治疗晚期外伤性癫痫的中药丸上述的原料组份中，每组份原料的药理及药效为：
水蛭：性味咸苦，平，有毒。主治损伤瘀血作痛、痈肿、丹毒等症。
地龙:地龙性寒，味咸。功能：清热、平肝、止喘、通络。归肝、胃、肺、膀胱经。功能清热平肝、熄风止痉、平喘、利尿、通络除痹。主治高热烦躁、惊痫抽搐、肺热喘咳、热结尿闭、痹痛肢麻、半身不遂，以及疮疡肿毒等证。主治高热狂燥，惊风抽搐，风热头痛，目赤、半身不遂等。
当归:甘、辛、温。归肝、心、脾经。补血；活血；调经止痛；润燥滑肠。主血虚诸证；症瘕结聚；崩漏；虚寒腹痛；痿痹；肌肤麻木；肠燥便难；赤痢后重；痈疽疮疡；跌扑损伤。
桃仁:活血祛瘀，润肠通便。用于癓瘕痞块，跌扑损伤，肠燥便秘。桃仁性甘平、味苦，入肺、肝、大肠经;有破血行瘀，润燥滑肠的功效;治经闭、痛经、瘕瘕痞块，跌打损伤、肠燥便秘。
天麻:天麻为多年生草本植物，分布于全国大部分地区。其干燥块茎亦称天麻，是一味常用而较名贵的中药，临床多用于头痛眩晕、肢体麻木、小儿惊风、癫痫、抽搐、破伤风等症。
天麻：天麻为多年生草本植物，分布于全国大部分地区。其干燥块茎亦称天麻，是一味常用而较名贵的中药，临床多用于头痛眩晕、肢体麻木、小儿惊风、癫痫、抽搐、破伤风等症。
郁金:行气解郁，凉血破瘀。治失心癫狂，热病神昏。
胆南星:胆南星由天南星的细粉与牛、羊或猪胆汁经加工而成，或为生天南星细粉与牛、羊或猪胆汁经发酵加工而成。清火化痰，镇惊定痼。治中风痰迷，惊风癫痫，痰火喘嗽，头风眩晕。
僵蚕:僵蚕别名天虫、姜蚕。是一种比较特殊的产品，它又名白僵蚕，是家蚕幼虫在吐丝前因感染白僵菌而发病致死的干涸硬化虫体，由于其体表密布白色菌丝和分生孢子，形似一层白膜，故名，主要用于惊风抽搐，咽喉肿痛，颌下淋巴结炎，面神经麻痹，皮肤瘙痒等病症。临床多用于治热咳，痰喘，吐血，崩，带，跌打损伤，风湿痛，疮毒等，近年来其应用范围和领域不断扩大。
党参：甘，平。补中益气，和胃生津，祛痰止咳。用于脾虚食少便溏，四肢无力，心悸，气短，口干，自汗，脱肛，阴挺。
甘草:补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药。用于脾胃虚弱，倦怠乏力，心悸气短，咳嗽痰多，脘腹、四肢挛急疼痛，痈肿疮毒，缓解药物毒性、烈性。用于心气虚，心悸怔忡，脉结代，以及脾胃气虚，倦怠乏力等。前者，常与桂枝配伍，如桂枝甘草汤、炙甘草汤。后者，常与党参、白术等同用，如四君子汤、理中丸等。
代赭石:苦，寒。归肝、心、肺、胃经。平肝潜阳，降肺胃逆气，凉血止血。
山药:山药味甘，补而不腻，香而不燥，益智健脑,益气补气，止咳定喘,补中益气，可使人耳聪目明。
泽泻:甘，寒。入肾、膀胱经。利水，渗湿，泄热。治小便不利，水肿胀满，呕吐，泻痢，痰饮，脚气，淋病，尿血。
丹参:可活血调经，祛疲止痛，清心除烦，养血安神，《本草汇言》：“丹参，善治血分，去滞生新”，《明理论》言一味丹参，功同四物。患者病程较长，“久病入络”、“久病必虚”，故使用丹参活血化疲，且具有保护心肌、安神等作用。
川芎:辛，温。入肝、胆经。行气开郁，法风燥湿，活血止痛。治风冷头痛旋晕，胁痛腹疼，寒痹筋挛，经闭，难产，产后瘀阻块痛，痈疽疮疡。用于月经不调，经闭痛经，瘕腹痛，胸胁刺痛，跌扑肿痛，头痛，风湿痹痛。
茯苓:性味甘淡，为孔菌科真菌茯苓的干燥菌核，有利水渗湿，健脾安神的作用。即《神农本草经》：“主胸胁逆气，忧圭惊邪，恐悸利小便，久服安魂养神、不饥、延年。”
当前中医学研究认为，癫痫发作的直接病理机制是大脑气血运行不畅、气血阻塞、经络不通。当颅脑损伤致瘀血内停、血流不畅，瘀血阻络，就会引发外伤性痫症，尤其是颅脑损伤者在外部伤口愈合很长时间后发作的癫痫，即晚期外伤性癫痫，一般指颅脑损伤愈后四周发生的癫痫，可导致脑组织的严重缺氧，使患者进一步加重其脑组织的病理损伤及脑神经生化改变，治疗处理更复杂，若癫痫发作持续状态长，更能造成脑组织的不可逆损伤。因此，从中医医学的通络散瘀、活血化瘀入手，改善全身血液循环，尤其是改善脑部供血、供氧，以水蛭、代赭石、地龙、僵蚕、胆南星为君药,以川芎、当归、桃仁、丹参、天麻、郁金为臣药，以党参、茯苓、山药、泽泻佐药,以甘草为使药组方，配制成本发明中药丸，针对不同晚期外伤性癫痫发病者辅以对症西药（根据发作类型用药，大发作和局限性发作者,予以丙戊酸钠口服，每次两片，每日三次；小发作者予以丙戊酸钠口服，每次一片，每日三次；精神运动发作者予以卡马西平口服，每次两片，每日三次；肌阵挛发作者予以安定片口服，每次一片，每日三次。）配合治疗，取得不错的疗效，治愈率高，反复发作率大大下降。
该治疗晚期外伤性癫痫的中药丸的组方中的水蛭、桃仁活血化瘀、通络散结；丹参可活血调经，祛疲止痛，清心除烦，养血安神；川芎和当归补血、活血；地龙熄风止痉、通络除痹；胆南星清火化痰、镇惊定痫。天麻用以平肝熄风、通脉开窍；僵蚕祛风解痉、化痰散结；郁金化痰熄风、醒脑开窍；党参和甘草扶正达邪，健脾和中；茯苓具有利水渗湿，健脾安神的作用。代赭石可镇心定痫。现代药理研究发现，水蛭具有活血、散瘀、通经的功效，可明显改善脑血管动力学指标，缓解大脑皮层异常放电，对癫痫的防治具有重要的临床作用。天麻具有行气活血、抗惊厥作用，可抑制以谷氨酸为主的兴奋性神经递质的病理性释放，稳定膜电位，从而具有抗癫痫作用。
本发明与现有技术相比的有益效果在于：
该治疗晚期外伤性癫痫的中药丸，通过君药：水蛭、代赭石、地龙、僵蚕、胆南星，臣药：川芎、当归、桃仁、丹参、天麻、郁金，佐药：党参、茯苓、山药、泽泻，使药：甘草为病患发作者活血散瘀通经，清火化痰，行气活血，明显改善脑血管动力，缓解大脑皮层异常放电，镇惊定痫抗惊厥。再针对不同癫痫发作个体辅以西药，治疗晚期外伤性癫痫不仅疗效肯定，能快速缓解和消除癫痫发作者的症状，而且非常有助于改善预后和预防顽固性癫痫发作。治愈率高，治疗方法简便，无毒副作用，价格低廉，服用方便。无论是近期还是远期疗效均明显优于纯西药治疗方式。
具体实施方式
下面对该治疗晚期外伤性癫痫的中药丸的实施方式作进一步详细说明：
一种治疗晚期外伤性癫痫的中药丸，其特征在于：它是通过下述重量份的原料制成：
水蛭10-40份 地龙10-18份 当归10-18份
桃仁10-18份 天麻10-18份 郁金10-15份
胆南星10-18份 僵蚕10-18份 党参10-15份
甘草20-50份 代赭石10-30份
山药10-18份 泽泻10-18份 丹参10-18份
川芎10-30份 茯苓10-18份
该治疗晚期外伤性癫痫的中药丸，根据中医辩证论治和标本兼治原则，及癫痫病的发病病因，通过本发明申请人数年临床实践和探索，采用水蛭、地龙、当归、桃仁、天麻、郁金、胆南星、僵蚕、党参、甘草、代赭石、山药、泽泻、丹参、川芎、茯苓这16味中草药组合配方，其中的君药为：水蛭、代赭石、地龙、僵蚕、胆南星,臣药为：川芎、当归、桃仁、丹参、天麻、郁金，佐药为：党参、茯苓、山药、泽泻，使药为：甘草。并在临床中辅以西药（根据发作类型用药，大发作和局限性发作者,予以丙戊酸钠口服，每次两片，每日三次；小发作者予以丙戊酸钠口服，每次一片，每日三次；精神运动发作者予以卡马西平口服，每次两片，每日三次；肌阵挛发作者予以安定片口服，每次一片，每日三次。）即中西医结合针对治疗晚期外伤性癫痫取得了稳定和不错的疗效，不仅能快速缓解和消除癫痫症状，而且对改善预后、减少发病次数、预防癫痫发作的效果明显优于纯西药治疗，有效提高了治愈率。
优选的，上述中药组合物由以下重量份的组分组成：
水蛭20-40份 地龙15-18份 当归15-18份
桃仁15-18份 天麻15-18份 郁金12-15份
胆南星15-18份 僵蚕15-18份 党参10-15份
甘草40-50份 代赭石20-30份
山药15-18份 泽泻15-18份 丹参15-18份
川芎20-30份 茯苓15-18份
进一步优选的，上述中药组合物由以下重量份的组分组成：
水蛭20份 地龙15份 当归15份
桃仁15份 天麻15份 郁金12份
胆南星15份 僵蚕15份 党参10份
甘草40份 代赭石20份
山药15份 泽泻15份 丹参15份
川芎20份 茯苓15份
所述治疗晚期外伤性癫痫的中药丸是通过如下方法制作而成的：先将水蛭、泽泻、当归、茯苓粉碎成粗粉备用，余药煎煮二次，第一次加水2000ml煮沸3小时，第二次加水1000ml煮沸2小时，滤液合并，静置24小时，取上清液浓缩至稠膏，将稠膏倒入上诉由水蛭、泽泻、当归、茯苓粉碎而成的粗粉中混匀，80℃干燥，粉碎成细粉，过80目筛，用纯净水泛丸，即得成品，0.38g/丸，瓶装密封，60g/瓶。
实施例1
本实施例治疗晚期外伤性癫痫的中药丸由以下重量份的组分组成：水蛭20份，地龙15份，当归15份，桃仁15份，天麻15份，郁金125份，胆南星15份，僵蚕15份，党参10份， 甘草40份，代赭石20份，山药15份，泽泻15份，丹参15份，川芎20份，茯苓15份。先将上述重量份的水蛭、泽泻、当归、茯苓粉碎成粗粉备用，将其余重量份的余药煎煮二次，第一次加水2000ml煮沸3小时，第二次加水1000ml煮沸2小时，滤液合并，静置24小时，取上清液浓缩至稠膏，将稠膏倒入上诉由水蛭、泽泻、当归、茯苓粉碎而成的粗粉中混匀，80℃干燥，粉碎成细粉，过80目筛，用纯净水泛丸，即得成品，0.38g/丸，瓶装密封，60g/瓶。
实施例2
本实施例治疗晚期外伤性癫痫的中药丸由以下重量份的组分组成：水蛭40份，地龙18份，当归18份，桃仁18份，天麻18份，郁金15份，胆南星18份，僵蚕18份，党参15份，甘草50份，代赭石30份，山药18份，泽泻18份，丹参18份，川芎30份，茯苓18份。先将上述重量份的水蛭、泽泻、当归、茯苓粉碎成粗粉备用，将其余重量份的余药煎煮二次，第一次加水2000ml煮沸3小时，第二次加水1000ml煮沸2小时，滤液合并，静置24小时，取上清液浓缩至稠膏，将稠膏倒入上诉由水蛭、泽泻、当归、茯苓粉碎而成的粗粉中混匀，80℃干燥，粉碎成细粉，过80目筛，用纯净水泛丸，即得成品，0.38g/丸，瓶装密封，60g/瓶。
实施例3
本实施例治疗晚期外伤性癫痫的中药丸由以下重量份的组分组成：水蛭15份，地龙14份，当归14份，桃仁14份，天麻14份，郁金12份，胆南星14份，僵蚕14份，党参12份，甘草30份，代赭石20份，山药14份，泽泻14份，丹参14份，川芎20份，茯苓14份。先将上述重量份的水蛭、泽泻、当归、茯苓粉碎成粗粉备用，将其余重量份的余药煎煮二次，第一次加水2000ml煮沸3小时，第二次加水1000ml煮沸2小时，滤液合并，静置24小时，取上清液浓缩至稠膏，将稠膏倒入上诉由水蛭、泽泻、当归、茯苓粉碎而成的粗粉中混匀，80℃干燥，粉碎成细粉，过80目筛，用纯净水泛丸，即得成品，0.38g/丸，瓶装密封，60g/瓶。
本发明申请人对就诊的67例外伤性癫痫患者进行了临床观察，其临床数据如下：
1. 一般资料
1.1研究对象
本次研究对象为2012年1月-2016年1月在湖北省公安县中医院收治的晚期外伤性癫痫患者67例。按随机数字表将67例晚期外伤性癫痫患者随机分为两组: 本发明丸组34例，其中大发作18例，局限性发作6例，小发作4例，精神运动性发作4例，肌陈挛发作2例；男性19例，女性15例；年龄5～76岁，平均52.4岁。对照组33例, 其中大发作17例，局限性发作6例，小发作5例，精神运动性发作4例，肌陈挛发作1例；男18例，女15例；年龄6～75岁，平均51.6岁。经统计学分析，两组患者发作类型、性别、年龄等一般临床资料的差异无显著性(P>0.05)，具有可比性（见表1、表2、表3）。
表1 两组患者发作类型比较
注：与对照组相应值比，x^2=0.9 P>0.05
表2 两组患者性别比较
注：与对照组相应值比，x^2=1.3 P>0.05
表3 两组患者年龄比较
注：与对照组相应值比，x^2=1.2 P>0.05
1.2实验室检查
对本发明服药组患者进行脑电图、头颅CT或MRI检查，其中有不同程度脑软化灶60例；EEG检查49例有癫痫样波，其中35例脑电图背景异常，表现为弥散性低波伏θ波和波幅不对称等。
1.3诊断依据
67例患者依据临床表现，并经脑电图检查确诊，既往无癫痫发作史，而于外伤4周后首次出现癫痫发作，全部病例均符合晚期外伤性癫痫的诊断标准。
1.4 颅脑损伤的诊断标准：
所有颅脑损伤患者均经头颅CT或MRI证实有开放性或闭合性颅脑损伤。
1.5 晚期外伤性癫痫的诊断标准：
①发病前有明确颅脑损伤史；
②既往无癫痫病史；
③具备脑电生理学依据：具有棘波、尖波、棘慢波、尖慢波、多棘慢波等典型癫痫波及局灶高幅波；
④具有癫痫发作的典型临床表现：发作性意识障碍、抽搐、昏厥、双目上吊、口吐涎沫等；
⑤除外其它致癫痫的病史：感染、脑血管病、颅内占位性病变、脑发育异常等；
⑥外伤4周后首次出现癫痫发作。
1.6 癫痫的分类标准：
1.6.1 按照1981年国际抗癫痫联盟分类和名词委员会推荐的分类方法，以癫痫发作的临床表现和脑电图特征分为全面性发作、部分性发作和不能分类的发作；
1.6.2 PTE发作分为3类：临床根据外伤后发病时间分为早期（脑外伤后24小时内发生癫痫）、中期（脑外伤后1天至4周发生癫痫）、晚期（脑外伤后4周以后发生癫痫）。
1.7 病例纳入标准：
①符合晚期外伤性癫痫的诊断标准；
②年龄在5～76岁之间；
③常规西药治疗疗效不佳者
1.8 病例排除标准：
①年龄在5岁以下或76岁以上者；
②服用常规抗癫痫西药和/或本发明中药丸服药后出现不良反应者；
③合并有其他原发性疾病者；
④依从性差，不按时服药，不定期复查者。
2. 方法
2.1治疗方法
对照组采用西医常规抗癫痫药物治疗。根据发作类型用药，大发作和局限性发作者,予以丙戊酸钠口服，每次两片，每日三次；小发作者予以丙戊酸钠口服，每次一片，每日三次；精神运动发作者予以卡马西平口服，每次两片，每日三次；肌阵挛发作者予以安定片口服，每次一片，每日三次，并定期监测药物浓度。
本发明服药组采用中西医结合治疗，在对照组的基础上，同时给予本发明丸口服。本发明丸（治疗晚期外伤性癫痫的中药丸）的药物组成为：水蛭，地龙，当归，桃仁，天麻，郁金，胆南星，僵蚕，党参、甘草、代赭石、山药、泽泻、丹参、川芎、茯苓。每日三次，每次6g，空腹服用，儿童酌减。若不能口服者，将药溶化后从胃管注入。
两年后比较两组疗效。
两组患者均治疗观察两年，定期监测药物浓度，复查脑电图，了解患者发作情况。
2.2 临床疗效评定
疗效标准：参照《癫痫病学》中癫痫病疗效标准，临床治愈：两年无临床发作,药物减量并逐渐停药无临床发作,脑电图可见癫痫波减少或消失。显效:临床发作次数减少，脑电图癫痫波减少，背景脑波有好转。无效：不能控制癫痫发作。
2.3统计学方法
采用SPSS16.0统计软件进行数据分析，根据数据的不同，计数资料的比较用检验。
结果
3.1本发明服药组与对照组患者临床疗效观察
两组患者临床疗效对比，本发明丸组治愈率为58.82％，显效率为23.53％，总有效率82.35％；对照组治愈率为45.45％，显效率为15.15％，总有效率60.61％。两组均无中途中断治疗病例，两组患者总有效率有显著差异（P<0.05），说明本发明丸（治疗晚期外伤性癫痫的中药丸）结合西药治疗晚期外伤性癫痫优势明显。 具体结果见表4。
表4 两组临床疗效比较
注：与对照组相应值比，x^2=3.9 P<0.05
3.2 不良反应
两组患者治疗前后未见明显不良反应。
以上所述只是本发明的较佳实施例而已，上述举例说明不对本发明的实质内容作任何形式上的限制，所属技术领域的普通技术人员在阅读了本说明书后依据本发明的技术实质对以上具体实施方式所作的任何简单修改或变形，以及可能利用上述揭示的技术内容加以变更或修饰为等同变化的等效实施例，均仍属于本发明技术方案的范围内，而不背离本发明的实质和范围。
Claims (4)
1.一种治疗晚期外伤性癫痫的中药丸，其特征在于：它是通过下述重量份的原料制成：
水蛭10-40份 地龙10-18份 当归10-18份
桃仁10-18份 天麻10-18份 郁金10-15份
胆南星10-18份 僵蚕10-18份 党参10-15份
甘草20-50份 代赭石10-30份
山药10-18份 泽泻10-18份 丹参10-18份
川芎10-30份 茯苓10-18份
其中：君药为水蛭、代赭石、地龙、僵蚕、胆南星，臣药为：川芎、当归、桃仁、丹参、天麻、郁金,佐药为：党参、茯苓、山药、泽泻，使药为：甘草。
2.根据权利要求1所述的一种治疗晚期外伤性癫痫的中药丸，其特征在于：其中各原料的重量份为：
水蛭20-40份 地龙15-18份 当归15-18份
桃仁15-18份 天麻15-18份 郁金12-15份
胆南星15-18份 僵蚕15-18份 党参10-15份
甘草40-50份 代赭石20-30份
山药15-18份 泽泻15-18份 丹参15-18份
川芎20-30份 茯苓15-18份。
3.根据权利要求1所述的一种治疗晚期外伤性癫痫的中药丸，其特征在于：其中各原料的重量份为：
水蛭20份 地龙15份 当归15份
桃仁15份 天麻15份 郁金12份
胆南星15份 僵蚕15份 党参10份
甘草40份 代赭石20份
山药15份 泽泻15份 丹参15份
川芎20份 茯苓15份。
4.一种治疗晚期外伤性癫痫的中药丸的制备方法，其特征在于：将水蛭、泽泻、当归、茯苓粉碎成粗粉备用，余药煎煮二次，第一次加水2000ml煮沸3小时，第二次加水1000ml煮沸2小时，滤液合并，静置24小时，取上清液浓缩至稠膏，将稠膏倒入上诉由水蛭、泽泻、当归、茯苓粉碎而成的粗粉中混匀，80℃干燥，粉碎成细粉，过80目筛，用纯净水泛丸，即得成品，0.38g/丸，瓶装密封，60g/瓶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810376527.2A CN108273012A (zh) | 2018-04-25 | 2018-04-25 | 一种治疗晚期外伤性癫痫的中药丸 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810376527.2A CN108273012A (zh) | 2018-04-25 | 2018-04-25 | 一种治疗晚期外伤性癫痫的中药丸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108273012A true CN108273012A (zh) | 2018-07-13 |
Family
ID=62812136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810376527.2A Withdrawn CN108273012A (zh) | 2018-04-25 | 2018-04-25 | 一种治疗晚期外伤性癫痫的中药丸 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108273012A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072798A1 (en) * | 2015-10-30 | 2017-05-04 | Nisarga Biotech Private Limited | Therapeutic compositions comprising herbal extracts and essential oils for smoking and vaporization |
-
2018
- 2018-04-25 CN CN201810376527.2A patent/CN108273012A/zh not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072798A1 (en) * | 2015-10-30 | 2017-05-04 | Nisarga Biotech Private Limited | Therapeutic compositions comprising herbal extracts and essential oils for smoking and vaporization |
Non-Patent Citations (3)
| Title |
|---|
| 刘泉等: "通络散瘀汤治疗晚期外伤性癫痫临床研究", 《河南中医》 * |
| 叶国强等: "中西医结合治疗外伤性癫痫92例临床观察", 《河南外科学杂志》 * |
| 马凌波等: "中药配合卡马西平治疗外伤性癫痫60例临床观察", 《中医药临床杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520505B (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
| CN103405701A (zh) | 一种治疗胃肠道疾病的药物及其制备方法 | |
| CN104069162B (zh) | 一种治疗痛风性关节炎及各种骨关节疼痛的中药 | |
| CN104491716A (zh) | 治疗淋巴瘤的中药胶囊及其制备方法 | |
| CN105056020B (zh) | 一种治疗痛风的灵仙丸及其制备方法 | |
| CN106039109A (zh) | 防治寒湿阻络型的类风湿性关节炎的中药药酒 | |
| CN106266436A (zh) | 一种滋阴补肾填精益髓的组合物 | |
| KR101840572B1 (ko) | 갱년기 증상의 완화 및 치료용 생약 혼합 조성물 및 그 제조방법 | |
| CN110141646A (zh) | 一组用于治疗中风的中药 | |
| CN102813888B (zh) | 一种治疗癫痫病的中药组合物 | |
| CN105434739A (zh) | 一种治疗霰粒肿的中药组合物及其制备方法 | |
| CN108273012A (zh) | 一种治疗晚期外伤性癫痫的中药丸 | |
| CN101590114B (zh) | 一种治疗多发性硬化的药物及其制备方法 | |
| CN110478416A (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
| CN105727158A (zh) | 一种治疗淋巴瘤的中药胶囊及其制备方法 | |
| CN104547384A (zh) | 一种治疗百草枯中毒的口服液及制备方法 | |
| CN103961578A (zh) | 一种治疗神经衰弱的中药药酒 | |
| CN100406035C (zh) | 一种治疗腰椎间盘突出症的中药制剂 | |
| CN103330911B (zh) | 治疗冠心病的中药组合物粉剂及其制备方法 | |
| CN105288298A (zh) | 一种用于脑动脉瘤后遗症的中药制剂及其制备方法 | |
| CN105288212A (zh) | 一种治疗阴虚火旺型失眠的中药组合物及其制备方法 | |
| CN104547695B (zh) | 一种用于治疗三叉神经痛的药物组合物及其应用 | |
| CN104873896A (zh) | 一种治疗高血压引发中风的中药组合物 | |
| CN103638330A (zh) | 一种治疗气血两虚型偏头痛的中药制剂及其制备方法 | |
| CN103735826A (zh) | 一种治疗心律失常的中草药配方及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180713 |